Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Searcey

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
Chemical Communications (Cambridge, England)|October 18, 2011
Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activityKlaus Pors, Paul M Loadman, Steven D Shnyder, et al.
RSC Medicinal Chemistry|May 27, 2021
Peptide directed phthalocyanine-gold nanoparticles for selective photodynamic therapy of EGFR overexpressing cancersZoë Rachael Goddard, Andrew Michael Beekman, Marco M D Cominetti, et al.
Bioorganic & Medicinal Chemistry|May 1, 2021
Probing cytochrome P450 (CYP) bioactivation with chloromethylindoline bioprecursors derived from the duocarmycin family of compoundsNatalia Ortuzar, Kersti Karu, Daniela Presa, et al.
Molecular Cancer Therapeutics|October 4, 2012
Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladderMark Sutherland, Jason H Gill, Paul M Loadman, et al.
Journal of Medicinal Chemistry|July 13, 2013
Re-engineering of the duocarmycin structural architecture enables bioprecursor development targeting CYP1A1 and CYP2W1 for biological activityHelen M Sheldrake, Sandra Travica, Inger Johansson, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
Chemical Communications (Cambridge, England)|October 18, 2011
Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activityKlaus Pors, Paul M Loadman, Steven D Shnyder, et al.
RSC Medicinal Chemistry|May 27, 2021
Peptide directed phthalocyanine-gold nanoparticles for selective photodynamic therapy of EGFR overexpressing cancersZoë Rachael Goddard, Andrew Michael Beekman, Marco M D Cominetti, et al.
Bioorganic & Medicinal Chemistry|May 1, 2021
Probing cytochrome P450 (CYP) bioactivation with chloromethylindoline bioprecursors derived from the duocarmycin family of compoundsNatalia Ortuzar, Kersti Karu, Daniela Presa, et al.
Molecular Cancer Therapeutics|October 4, 2012
Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladderMark Sutherland, Jason H Gill, Paul M Loadman, et al.
Journal of Medicinal Chemistry|July 13, 2013
Re-engineering of the duocarmycin structural architecture enables bioprecursor development targeting CYP1A1 and CYP2W1 for biological activityHelen M Sheldrake, Sandra Travica, Inger Johansson, et al.
Pageof 6